Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Purchases 5,399 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 5,399 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was acquired at an average cost of $8.11 per share, for a total transaction of $43,785.89. Following the completion of the transaction, the insider now directly owns 2,948,160 shares in the company, valued at $23,909,577.60. This represents a 0.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Wednesday, June 18th, Marlio Charles Mosseri purchased 28,043 shares of Nuvectis Pharma stock. The stock was acquired at an average price of $8.05 per share, with a total value of $225,746.15.
• On Monday, May 12th, Marlio Charles Mosseri acquired 21,167 shares of Nuvectis Pharma stock. The shares were acquired at an average cost of $8.11 per share, for a total transaction of $171,664.37.
• On Thursday, May 8th, Marlio Charles Mosseri bought 2,650 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $8.65 per share, with a total value of $22,922.50.
• On Tuesday, May 6th, Marlio Charles Mosseri purchased 12,444 shares of Nuvectis Pharma stock. The shares were bought at an average cost of $8.59 per share, for a total transaction of $106,893.96.

Nuvectis Pharma Stock Performance

Shares of NVCT stock traded down $0.17 during mid-day trading on Monday, reaching $7.96. 116,327 shares of the company's stock traded hands, compared to its average volume of 129,219. The firm has a market capitalization of $166.28 million, a PE ratio of -7.04 and a beta of -0.16. Nuvectis Pharma, Inc. has a 12 month low of $4.44 and a 12 month high of $11.80. The firm has a 50 day moving average price of $9.28 and a two-hundred day moving average price of $7.72.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03. As a group, equities analysts expect that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Nuvectis Pharma

Hedge funds and other institutional investors have recently modified their holdings of the company. Baldwin Wealth Partners LLC MA raised its holdings in Nuvectis Pharma by 0.7% during the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock valued at $3,502,000 after acquiring an additional 2,500 shares during the period. Baxter Bros Inc. raised its stake in Nuvectis Pharma by 20.0% during the 4th quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock valued at $81,000 after purchasing an additional 2,500 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Nuvectis Pharma in the 4th quarter worth approximately $34,000. Blue Zone Wealth Advisors LLC bought a new position in Nuvectis Pharma in the 1st quarter worth approximately $102,000. Finally, Northern Trust Corp boosted its stake in Nuvectis Pharma by 68.7% in the 4th quarter. Northern Trust Corp now owns 25,725 shares of the company's stock worth $139,000 after purchasing an additional 10,472 shares during the period. 96.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVCT has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Nuvectis Pharma from a "sell" rating to a "hold" rating in a research report on Saturday. Laidlaw began coverage on Nuvectis Pharma in a report on Monday, March 17th. They set a "buy" rating and a $19.00 price target on the stock. Maxim Group assumed coverage on Nuvectis Pharma in a report on Wednesday, April 2nd. They issued a "buy" rating and a $17.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 price objective (up previously from $11.00) on shares of Nuvectis Pharma in a research report on Wednesday, April 30th.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.